Long-term effects of Lee Silverman Voice Treatment on daily voice use in Parkinson’s disease as measured with a portable voice accumulator

References

• Duffy JR. Motor speech disorders: substrates, differential diagnosis and management. 3rd ed. St Louis, Missouri: Elsevier Mosby; 2013.
   Google Scholar
• Weiner WJ, Singer C. Parkinson’s disease and nonpharmacologic treatment programs. J Am Geriatr Soc 1989;37:359–63.
   PubMed Web of Science ®Google Scholar
• Ho AK, Bradshaw JL, Iansek R. Volume perception in parkinsonian speech. Mov Disord 2000;15:1125–31.
   PubMed Web of Science ®Google Scholar
• Klockgether T, Borutta M, Rapp H, et al. A defect of kinesthesia in Parkinson’s disease. Mov Disord 1995;10:460–5.
   PubMed Web of Science ®Google Scholar
• Demirci M, Grill S, McShane L, Hallet M. A mismatch between kinesthetic and visual perception in Parkinson’s disease. Ann Neurol 1997;41:781–8.
   PubMed Web of Science ®Google Scholar
• Ho AK, Bradshaw JL, Iansek R, Alfredson R. Speech volume regulation in Parkinson’s disease: effects of implicit cues and explicit instructions. Neuropsychologia 1999;37:1453–60.
   PubMed Web of Science ®Google Scholar
• Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson’s disease. Expert Rev Neurother 2008;8:297–311.
   PubMedGoogle Scholar
• Ho AK, Bradshaw JL, Iansek R. For better or worse: the effect of levodopa on speech in Parkinson’s disease. Mov Disord 2008;23:574–80.
   PubMed Web of Science ®Google Scholar
• Plowman-Prine EK, Okun MS, Sapienza CM, et al. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. NeuroRehabilitation 2009;24:131–44.
   PubMed Web of Science ®Google Scholar
• Schulz GM, Hosey LA, Bradberry TJ, et al. Selective left, right and bilateral stimulation of subthalamic nuclei in Parkinson’s disease: differential effects on motor, speech and language function. J Parkinsons Dis 2012;2:29–40.
   PubMedGoogle Scholar
• Karlsson F, Olofsson K, Blomstedt P, et al. Pitch variability in patients with Parkinson’s disease: effects of deep brain stimulation of caudal zona incerta and subthalamic nucleus. J Speech Lang Hear Res 2013;56:1–9.
   PubMed Web of Science ®Google Scholar
• Karlsson F, Olofsson K, Blomstedt P, et al. Articulatory closure proficiency in patients with Parkinson's disease following deep brain stimulation of the subthalamic nucleus and caudal zona incerta. J Speech Lang Hear Res 2014;57:1178–90.
   PubMed Web of Science ®Google Scholar
• Sandström L, Hägglund P, Johansson L, et al. Speech intelligibility in Parkinson’s disease patients with zona incerta deep brain stimulation. Brain Behav 2016;5:e00394.
   Web of Science ®Google Scholar
• Atkinson-Clement C, Sadat J, Pinto S. Behavioral treatments for speech in Parkinson’s disaease: meta-analyses and review of the literature. Neurodegener Dis Manag 2015;5:233–48.
   PubMed Web of Science ®Google Scholar
• Fox C, Ebersbach G, Ramig L, Sapir S. LSVT LOUD and LSVT BIG: Behavioral treatment programs for speech and body movement in Parkinson disease. Parkinson’s Disease 2012;2012:391946.
   PubMed Web of Science ®Google Scholar
• Ramig LO, Fox C, Sapir S, Speech and voice disorders in Parkinson’s disease. In: Olanow W, et al., eds. Parkinson’s disease: non-motor and non-dopaminergic features. Oxford, UK: Blackwell Publishing Ltd; 2011.
   Google Scholar
• Ramig LO, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT) for patients with Parkinson’s disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001;71:493–8.
   PubMed Web of Science ®Google Scholar
• Constantinescu GA, Theodoros DG, Russel TG, et al. Home-based speech treatment for Parkinson’s disease delivered remotely: a case report. J Telemed Telecare 2010;16:100–4.
   PubMed Web of Science ®Google Scholar
• Constantinescu GA, Theodoros DG, Russel TG, et al. Treating disordered speech and voice in Parkinson’s disease online: a randomized controlled non-inferiority trial. Int J Lang Com Dis 2011;46:1–16.
   PubMed Web of Science ®Google Scholar
• Theodoros DG, Ramig LO. Telepractice supported delivery of LSVT LOUD. Sem Speech Lang Pat 2011;3:107–19.
   Google Scholar
• Theodoros DG, Hill AJ, Russel RG. Clinical and quality of life outcomes of speech treatment for Parkinson’s disease to the home via telerehabilitation: a non-inferiority randomized controlled trial. Am J Speech Lang Pat 2016;25:214–32.
   PubMed Web of Science ®Google Scholar
• Halpern A, Ramig LO, Matos C. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease. Am J Speech Lang Pathol 2012;21:354–67.
   PubMed Web of Science ®Google Scholar
• Lane H, Tranel B. The Lombard sign and the role of hearing in speech. J Speech Lang Hear Res 1971;14:677–709.
   Web of Science ®Google Scholar
• Arlinger S, Störande buller: Kunskapsöversikt för kriteriedokumentation [Disturbing noise: systematic review for criteria documentation]. Stockholm, Sweden: Arbetslivsinstitutet, Förlagstjänst; 1999.
   Google Scholar
• Adams SG, Lang AE. Can the Lombard effect be used to improve low voice intensity in Parkinson’s disease. Eur J Disord Com 1992;27:121–7.
   PubMedGoogle Scholar
• Sadagopan N, Huber JE. Effects of loudness cues on respiration in individuals with Parkinson’s disease. Mov Disord 2007;22:651–9.
   PubMed Web of Science ®Google Scholar
• Stathopoulos ET, Huber JE, Richardson K, et al. Increased vocal intensity due to the Lombard effect in speakers with Parkinson’s disease: simultaneous laryngeal and respiratory strategies. J Com Disord 2014;48:1–17.
   PubMed Web of Science ®Google Scholar
• Hartelius L, Svensson P, Dysartritestet. Stockholm, Sweden: Psykologiförlaget AB; 1990.
   Google Scholar
• Virebrand M, Real-time monitoring of voice characteristics using accelerometer and microphone measurements [unpublished master’s thesis]. Linköping, Sweden: Linköping University; 2011.
   Google Scholar
• Van Stan JH, Gustafsson J, Schalling E, Hillman RE. Direct comparison of three commercially available devices for voice ambulatory monitoring and biofeedback. SIG3 Perspect 2014;24:80–6.
   Google Scholar
• Hartelius L, Elmberg M, Holm R, et al. Living with dysarthria: evaluation of a self-report questionnaire. Folia Phoniatr Logop 2008;60:11–19.
   PubMed Web of Science ®Google Scholar
• Mehta DD, Woodbury Listfield R, Cheyne HA, et al. Duration of ambulatory monitoring needed to accurately estimate voice use. Portland, OR: Proceedings of InterSpeech: Annual Conference of the International Speech Communication Association; 2012.
   Google Scholar
• Södersten M, Lindhe C, Kunskapsöversikt: Yrkesrelaterade röststörningar och röstergonomi [Systematic review: work-related voice disorders and voice ergonomics]. Stockholm, Sweden: Arbetsmiljöverket; 2011.
   Google Scholar
• De Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525–35.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Gatz M, Bakaysa SL, et al. Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging 2008;29:1765–73.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Gatz M, Reyhnolds RA, et al. Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiol Aging 2011;32:1923.e1–e8.
   Web of Science ®Google Scholar